Prelude Capital Management, LLC Protara Therapeutics, Inc. Transaction History

Prelude Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.8 - $5.33 $36,041 - $68,607	-12,872 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.19 - $6.9 $16,688 - $27,482	-3,983 Reduced 23.63%	12,872 $66,000
Q4 2021 Feb 14, 2022	BUY	$6.15 - $7.76 $22,755 - $28,712	3,700 Added 28.13%	16,855 $114,000
Q3 2021 Nov 15, 2021	BUY	$6.38 - $9.3 $9,282 - $13,531	1,455 Added 12.44%	13,155 $91,000
Q2 2021 Aug 16, 2021	BUY	$8.68 - $16.99 $101,556 - $198,782	11,700 New	11,700 $114,000

10.7M

1.8K

Ticker TARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,267,400
Market Cap $26.9M
Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.